RemeGen (HKG:9995, SHA:688331) posted an attributable profit of 4.66 billion yuan in the first half of 2026, rebounding from an attributable loss of 449.57 billion yuan a year ago.
Earnings per share came in at 8.32 yuan, compared with a loss per share of 0.83 yuan a year earlier, according to a Monday filing with the Hong Kong Exchange.
Revenue surged year over year to 5.85 billion yuan from 1.09 billion, the biopharmaceutical company said.